Neurological and neuroendocrine-cytokine inter-relationship in the antiphospholipid syndrome.
Although many neurological deficits have been described in the antiphospholipid syndrome (APS), only stroke is well established and accepted as a diagnostic criterion in the disease. We presently review clinical data obtained from large series of cases regarding stroke, dementia, epilepsy, chorea, migraine, white-matter disease, and behavioral changes in APS, or linked-to-laboratory criteria such as antiphospholipid antibodies (aPL). The contribution of animal models to our understanding of these manifestations of APS is stressed, especially regarding the cognitive and behavioral aspects for which we have established model systems in the mouse. These models utilize immunization of mice with beta(2)-glycoprotein1, a central autoantigen in APS, which induces persistent high levels of aPLs. These mice develop hyperactive behavior after a period of four months, as well as deficits in learning and memory, and are potentially valuable as a system in which to study the pathogenesis and treatment of cognitive and behavioral aspects of APS. We have developed another model, in which IgGs from APS patients induce depolarization of brain synaptoneurosomes, and which may serve as a model for the pathogenesis of epilepsy in APS. Hormonal changes are another potential CNS manifestation of APS and this may be potentially linked to the systemic and central effects of cytokines such as interleukin-3. Better understanding of the link between APS and neurological or neuroendocrine manifestations other than stroke will reveal whether they can be used as clinical criteria for the diagnosis of APS and, it is hoped, lead to better treatment.
Neuroimmunology Service, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Joab
J
Chapman
Yehuda
Y
Shoenfeld
D000026:Abortion, Habitual / Q000209:etiology; D000818:Animals; D016736:Antiphospholipid Syndrome / Q000150:complications / Q000276:immunology / Q000503:physiopathology*; D001327:Autoimmune Diseases / Q000150:complications / Q000276:immunology / Q000503:physiopathology*; D001925:Brain Damage, Chronic / Q000209:etiology; D002819:Chorea / Q000209:etiology; D003072:Cognition Disorders / Q000209:etiology; D004827:Epilepsy / Q000209:etiology; D005260:Female; D006023:Glycoproteins / Q000276:immunology; D006801:Humans; D001523:Mental Disorders / Q000209:etiology; D051379:Mice; D020721:Nervous System Autoimmune Disease, Experimental / Q000276:immunology / Q000503:physiopathology / Q000523:psychology; D015213:Neuroimmunomodulation; D011247:Pregnancy; D011248:Pregnancy Complications / Q000276:immunology; D020521:Stroke / Q000209:etiology; D053482:beta 2-Glycoprotein I
D006023:Glycoproteins; D053482:beta 2-Glycoprotein I